Treatment Group | Â | Percent Protection from Outcomes | Percent Positive for Antibodies to FMDV NSPs | ||||
---|---|---|---|---|---|---|---|
N | Clinical FMD (1–15 dpcc) | FMDV or FMDV RNA in plasma (0–7, 9 dpcc) | FMDV RNA in oronasal fluid (0, 2, 4 dpcc) | FMDV RNA in probang (27, 34, 41 dpcc) | FMDV in probang (27, 34, 41 dpcc) | ||
T1: IDL challenged seeder steers | 10 | 0% | ND | ND | ND | ND | ND |
T2: 1o AdtA24 5 × 1010 PU vaccinated; Intermingled with 10 IDL challenged ‘seeder steers’ for 2–3 days | 12 | 100% No oronasal lesions | 100% | 0% | 18% | 27% | 9%a - 0 dpcc 91% -30 dpcc |
T3: 1o naïve; Intermingled with 10 IDL challenged ‘seeder steers’ for 2–3 days | 6 | 0% | 0% | 0% | 17% | 17% | 0% - 0 dpcc 100%-30 dpcc |
T4: 2o AdtA24 5 × 1010 PU vaccinated; Intermingled with 6 T2: 1o vaccinated and exposed steers (Room 1) | 4 | 100% No oronasal lesions | 100% | 100% | 100% | 100% | 0% - 0 and 30 dpcc |
T5: 2o naïve; Intermingled with 6 T2: 1o vaccinated and exposed steers (Room 2) | 4 | 100% No oronasal lesions | 100% | 75% | 50% | 100% | 0% - 0 and 30 dpcc |
T6: 2o naïve; Intermingled with 6 T3: 1o naïve and exposed steers (Room 3) | 4 | 0% | 0% | 0% | 25% | 25% | 0% - 0 dpcc 100%-30 dpcc |